Quantcast

Latest Female sexual arousal disorder Stories

2014-09-03 04:21:50

CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries. Richter is a European-based specialty...

2014-06-04 20:22:03

Persistent gender inequity at FDA has led to 26 approved drugs for men, and ZERO for women WASHINGTON, June 4, 2014 /PRNewswire-USNewswire/ -- Highlighting a persistent gender inequity at the Food and Drug Administration regarding the approval of treatments for the most common forms of sexual dysfunction, a diverse group of women's health and research organizations today launched Even the Score, a new advocacy campaign created to serve as a voice for American women who believe that it's time...

2014-05-28 08:30:26

Women treated with Tefina(TM) 0.6 mg reported a statistically significant increase in orgasms versus placebo TORONTO, May 28, 2014 /CNW/ - Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD). FOD, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of...

2014-05-20 08:34:24

Data show many women are not aware of hypoactive sexual desire disorder and often blame themselves for symptoms of low desire RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress and strains a woman's relationship with her...

2014-05-06 16:33:46

CRANBURY, N.J., May 6, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American Psychiatric Association (APA) 2014 Annual Meeting in New York, NY on Tuesday, May 6, 2014 at 2:30 PM ET. APA is the world's largest psychiatric organization. Bremelanotide is a first-in-class,...

2014-05-01 08:35:53

CRANBURY, N.J., May 1, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that a potential commercial partner has exercised its option for an exclusive license to bremelanotide for female sexual dysfunction (FSD) indications in the European Union and other European countries. The...

2014-04-29 08:35:16

CRANBURY, N.J., April 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28, 2014 at 3:45 PM local time. ACOG is the nation's leading group of...

2014-03-31 16:27:19

CRANBURY, N.J., March 31, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...

2014-02-11 12:26:47

Women's Groups Call on FDA to Restore Gender Equity in the Treatment of Sexual Disorders WASHINGTON, Feb. 11, 2014 /PRNewswire-USNewswire/ -- In response to the U.S. Food and Drug Administration's (FDA) decision to further delay approval of the first-ever drug to treat the most common female sexual disorder, the National Consumers League and the National Organization for Women, joined by women's health and advocacy organizations, are calling on the FDA to move swiftly to end the 16...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related